Key takeaways from ESMO24 Oral session on early stage breast cancer by Rasha Aboelhassan

Rasha Aboelhassan shared a post on LinkedIn:

”Mini oral session today. Early stage breast cancer conclusion and deeper thinking:

• Younger patients are in higher risk with less survival.
• It’s better to give ovarian suppression with AI to improve 5 years survival outcomes.
• Is it better to add ribociclib with AI as adjuvant therapy? Maybe.
• But unfortunately, younger patients are having less adherence to treatment.

Kivin Kalinsiky. Discussion:

• Tumor biopsy is different in younger patients, and there are more challenges upcoming.

To get better survival, please remember: more is not always better, you need to do more conversations with your patient.”

Source: Rasha Aboelhassan/LinkedIn

Rasha Aboelhassan is a Senior Oncology Consultant at Nasser Institute Hospital. In addition to her clinical role, she volunteers as a reviewer for the World Journal of Surgical Oncology, contributing to advancements in the field and is in the Editorial Staff of Egyptian Journal of Human Genetics.